PRECLINICAL DEVELOPMENT OF A BALANCED, TETRAVALENT, LIVE-ATTENUATED VACCINE AGAINST THE FOUR DENGUE VIRUS SEROTYPES

$4,443,544FY2022Defense Health AgencyDOD

Codagenix Inc

Investigators